Literature DB >> 8022236

Federal regulations and the care of patients with dementia in the nursing home.

J E Streim1, I R Katz.   

Abstract

More than half of the people residing in nursing homes in the United States have dementia. A long history of basic contradictions in the conceptualization of nursing home care in the United States has resulted in a serious mismatch between the needs of residents with dementia and the resources of nursing homes to care for these residents. Concern for this discrepancy, and the resultant inadequate and inappropriate care, provided a major impetus for nursing home reform. OBRA 87 was a broad public policy initiative intended to improve the quality of life of nursing home residents. The spirit of the legislation is embodied in federal regulations that explicitly recognize the importance of psychological and social domains of the lives of nursing home residents; restrict the use of psychotropic drugs and physical restraints; and advocate for activities and services to attain or maintain patients' highest practicable physical, mental, and psychosocial well-being. Although the impact of OBRA 87 on the quality of life of residents with dementia is unknown, the federal regulations constitute a major step in the movement for nursing home reform and toward improved quality of care.

Entities:  

Mesh:

Year:  1994        PMID: 8022236     DOI: 10.1016/s0025-7125(16)30141-9

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  3 in total

Review 1.  Administrative initiatives for reducing inappropriate prescribing of psychotropic drugs in nursing homes: how successful have they been?

Authors:  Carmel M Hughes; Kate L Lapane
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 2.  Lessons from geriatric psychiatry in the long-term care setting.

Authors:  J E Streim; D Oslin; I R Katz; P A Parmelee
Journal:  Psychiatr Q       Date:  1997

3.  Adverse drug effects in elderly people -- a disparity between clinical examination and adverse effects self-reported by the patient.

Authors:  Pasi Lampela; Sirpa Hartikainen; Raimo Sulkava; Risto Huupponen
Journal:  Eur J Clin Pharmacol       Date:  2007-03-10       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.